Anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies: incidence using different testing criteria, and case series
Vikram M K Joseph(University College Hospital), Patrick Kiely(University of Limerick), Rachel D. Wheeler(Protein Technologies (United Kingdom)), Vijay Hajela(University Hospitals Sussex NHS Foundation Trust), Soha Amar(Frimley Health NHS Foundation Trust), Christopher J Edwards(University Hospital Southampton NHS Foundation Trust), Efrem Eren(The Royal Free Hospital), Karen Smith(University Hospital Southampton NHS Foundation Trust), Rod Hughes(AstraZeneca (Singapore)), Tamara Forster(Department of Virology), Mark Lloyd, Emily Rose(University Hospital Southampton NHS Foundation Trust)
Cited by 11
Related Papers
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
|Annals of the Rheumatic Diseases|2022|1.9k
2022 update
|Radboud Repository (Radboud University)|2010|1.6k
EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis
|Annals of the Rheumatic Diseases|2013|668